Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities

A group of gene mutations has been identified to be strongly associated with secondary acute myeloid leukemias (AML) arising from prior myeloid neoplasms. The International Consensus Classification (ICC) and proposed 5th edition of the World Health Organization (WHO) classification differ by inclusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinberg, Olga K., Cantu, Miguel D., Gagan, Jeffrey, Madanat, Yazan F., Arber, Daniel A., Hasserjian, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435713/
https://www.ncbi.nlm.nih.gov/pubmed/37601841
http://dx.doi.org/10.1002/jha2.710
_version_ 1785092164117594112
author Weinberg, Olga K.
Cantu, Miguel D.
Gagan, Jeffrey
Madanat, Yazan F.
Arber, Daniel A.
Hasserjian, Robert P.
author_facet Weinberg, Olga K.
Cantu, Miguel D.
Gagan, Jeffrey
Madanat, Yazan F.
Arber, Daniel A.
Hasserjian, Robert P.
author_sort Weinberg, Olga K.
collection PubMed
description A group of gene mutations has been identified to be strongly associated with secondary acute myeloid leukemias (AML) arising from prior myeloid neoplasms. The International Consensus Classification (ICC) and proposed 5th edition of the World Health Organization (WHO) classification differ by inclusion of RUNX1. A recent study suggested that having two or more secondary mutations is associated with a particularly poor prognosis. In a study of 294 de novo AML patients, we found that patients with at least one ICC‐defined secondary mutation had shorter survival when compared to those without secondary mutations, and ICC/WHO groups of two or more mutations did not predict for worse outcomes.
format Online
Article
Text
id pubmed-10435713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104357132023-08-19 Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities Weinberg, Olga K. Cantu, Miguel D. Gagan, Jeffrey Madanat, Yazan F. Arber, Daniel A. Hasserjian, Robert P. EJHaem Short Reports A group of gene mutations has been identified to be strongly associated with secondary acute myeloid leukemias (AML) arising from prior myeloid neoplasms. The International Consensus Classification (ICC) and proposed 5th edition of the World Health Organization (WHO) classification differ by inclusion of RUNX1. A recent study suggested that having two or more secondary mutations is associated with a particularly poor prognosis. In a study of 294 de novo AML patients, we found that patients with at least one ICC‐defined secondary mutation had shorter survival when compared to those without secondary mutations, and ICC/WHO groups of two or more mutations did not predict for worse outcomes. John Wiley and Sons Inc. 2023-05-18 /pmc/articles/PMC10435713/ /pubmed/37601841 http://dx.doi.org/10.1002/jha2.710 Text en © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Weinberg, Olga K.
Cantu, Miguel D.
Gagan, Jeffrey
Madanat, Yazan F.
Arber, Daniel A.
Hasserjian, Robert P.
Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title_full Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title_fullStr Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title_full_unstemmed Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title_short Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
title_sort presence but not number of secondary type mutations influences outcome in de novo aml without mds‐associated or recurring cytogenetic abnormalities
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435713/
https://www.ncbi.nlm.nih.gov/pubmed/37601841
http://dx.doi.org/10.1002/jha2.710
work_keys_str_mv AT weinbergolgak presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities
AT cantumigueld presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities
AT gaganjeffrey presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities
AT madanatyazanf presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities
AT arberdaniela presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities
AT hasserjianrobertp presencebutnotnumberofsecondarytypemutationsinfluencesoutcomeindenovoamlwithoutmdsassociatedorrecurringcytogeneticabnormalities

Ejemplares similares